Perrigo Company plc Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets
Perrigo Company plc (PRGO) had Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets of $43.30 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Additional Information › Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets
us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets · last filed 2026-02-26
- 2025-12-31: Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets $43.30M.
- 2024-12-31: Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets $49.60M.
- 2023-12-31: Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets $52.60M.
- 2022-12-31: Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets $42.90M.
| Period end | Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets |
|---|---|
| 2025-12-31 | $43.30M 10-K · filed 2026-02-26 |
| 2024-12-31 | $49.60M 10-K · filed 2026-02-26 |
| 2023-12-31 | $52.60M 10-K · filed 2025-02-28 |
| 2022-12-31 | $42.90M 10-K · filed 2024-02-27 |
| 2021-12-31 | $70.00M 10-K · filed 2023-02-28 |
| 2020-12-31 | $71.10M 10-K · filed 2022-03-01 |
| 2019-12-31 | $62.10M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |